Research & Development
Grifols partners with BARDA to develop treatment for sulfur mustard eye injury
22 October 2024 - Spanish healthcare company Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ:GRFS), a manufacturer of plasma-derived medicines, announced on Tuesday that it has partnered with the Biomedical Adv...
Camurus receives complete response letter for CAM2029 NDA
22 October 2024 - Swedish biopharmaceutical company Camurus AB (STO:CAMX) reported on Tuesday that the US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the n...
Adcentrx Therapeutics' ADRX-0405 IND application approved by US FDA
22 October 2024 - California-based clinical-stage biotechnology company Adcentrx Therapeutics announced on Monday that it has received approval from the US Food and Drug Administration (FDA) for the c...
HELP Therapeutics' HiCM-188 IND application receives US FDA approval
22 October 2024 - HELP Therapeutics Co. Ltd, a China-based clinical-stage cell therapy company, announced on Tuesday that it has received approval from the US Food and Drug Administration (FDA) for it...
Ananda's cannabinoid medicines to feature in NHS epilepsy trials
21 October 2024 - Life sciences company Ananda Developments plc (AQSE: ANA) announced on Monday that its cannabinoid medicines, MRX2 and MRX2T, will be utilised in two National Institute for Health an...
AstraZeneca's Wainzua recommended for EU approval
21 October 2024 - AstraZeneca PLC (LSE: AZN) (STO: AZN (Nasdaq: AZN) a global, science-led biopharmaceutical company, announced on Monday that Wainzua (eplontersen) has received a positive recommendat...